I don’t see why a vaccination effort should be complex or expensive. Unlike COVID, A5N1 is not a newly discovered novel threat. We have a stockpiled vaccine al

I don’t see why a vaccination effort should be complex or expensive. Unlike COVID, A5N1 is not a newly discovered novel threat. We have a stockpiled vaccine already: https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-virus-vaccine-h5n1-national-stockpile https://www.fda.gov/vaccines-blood-biologics/vaccines/influe... And, more importantly, there is already a seasonal flu campaign every year. Interestingly, it was quadravalent until this year, when B/Yamagata was removed: https://www.cdc.gov/flu/season/2024-2025.html https://www.cdc.gov/flu/season/2024-2025.html And, unlike COVID, we already know how to make influenza vaccines. I haven’t seen any explanation for why the CDC did not add A5N1 to the seasonal flu. Doing so seems likely to massively reduce the severity of a potential outbreak of human-transmissible A5N1 and maybe even decrease the probability of an outbreak at all, and it would get about 50% coverage of the US population with no special effort at all beyond the effort of specifying it for the seasonal vaccine.